GNMS.F Stock Overview Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. More details
Rewards Risk Analysis No risks detected for GNMS.F from our risk checks.
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Genmab Historical stock prices Current Share Price DKK 203.33 52 Week High DKK 334.33 52 Week Low DKK 192.20 Beta 0.87 1 Month Change -3.53% 3 Month Change -22.45% 1 Year Change -34.46% 3 Year Change -49.13% 5 Year Change -8.82% Change since IPO 1,157.45%
Recent News & Updates
Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial Dec 08
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate Sep 16
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Aug 20
Genmab A/S Announces Executive Changes Aug 16
Genmab A/S Takes Full Control of Acasunlimab Development Program Aug 06
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY Jun 27 See more updates
Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial Dec 08
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate Sep 16
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Aug 20
Genmab A/S Announces Executive Changes Aug 16
Genmab A/S Takes Full Control of Acasunlimab Development Program Aug 06
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY Jun 27
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma Jun 05 Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc. May 22
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress May 15 Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer Apr 30
Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion. Apr 05
Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion. Apr 03
Genmab A/S Announces Executive Changes Mar 14 Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma Feb 27
Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®? Feb 03
Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc Jan 23 Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application Jan 10
Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma Dec 11
Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma Nov 29
Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma Nov 28
Genmab A/S Revises Earnings Guidance for the Year 2023 Nov 08
Genmab A/S, Annual General Meeting, Mar 13, 2024 Oct 28 Genmab A/S to Report Q1, 2024 Results on May 02, 2024 Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial Oct 24
Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy Sep 05
Genmab A/S Revises Earning Guidance for the Year 2023 Jul 29
Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma Jul 23 AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) Jun 28
Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’ Jun 23
Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023 Jun 09
U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma May 20
Genmab A/S Provides Earnings Guidance for 2023 May 11
Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Dec 22
Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting Dec 13 Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023
Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl) Nov 22 Genmab Provides Earnings Guidance for Year 2022
Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration Oct 29
Genmab A/S Revises Earnings Guidance for the Year 2022 Aug 09
Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Jul 01
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium Jun 13
Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting Jun 07
Genmab A/S Revises Earnings Guidance for 2022 May 12
AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) Apr 14
Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors Mar 30
Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer Mar 03
Genmab A/S Provides Earnings Guidance for the Year 2022 Feb 18
Genmab A/S Provides Earnings Guidance for the Year 2022 Feb 17
Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT Dec 15
U.S. Food and Drug Administration Grants Approval to TIVDAK Sep 24 Seagen Inc. and Genmab A/S Announce FDA Accelerated Approval for TIVDAK™ (Tisotumab Vedotin-Tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Genmab A/S Announces the Lancet Published the Results of FIH Trial Sep 10
Genmab A/S Improves Revenue Guidance for the Full Year of Fiscal 2021 Aug 12
Genmab A/S Announces That Janssen Has Received European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-Chain (Al) Amyloidosis Jun 23 Genmab Announces Janssen Received Positive CHMP Opinion Recommending DARZALEX (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress May 21
Genmab A/S Reaffirms Financial Guidance for Fiscal 2021 May 06
Genmab A/S Provides Revenue Guidance for the Full Year of Fiscal 2021 Apr 15
Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines Feb 23
Seagen Inc. and Genmab A/S Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Feb 11
CHMP Issues Positive Opinion Recommending Genmab Ofatumumab in Relapsing Multiple Sclerosis Jan 31 Shareholder Returns GNMS.F US Biotechs US Market 7D -4.5% -6.5% -4.0% 1Y -34.5% 1.3% 24.0%
See full shareholder returns
Return vs Industry: GNMS.F underperformed the US Biotechs industry which returned 3.1% over the past year.
Return vs Market: GNMS.F underperformed the US Market which returned 26.1% over the past year.
Price Volatility Is GNMS.F's price volatile compared to industry and market? GNMS.F volatility GNMS.F Average Weekly Movement 7.6% Biotechs Industry Average Movement 10.7% Market Average Movement 6.4% 10% most volatile stocks in US Market 16.8% 10% least volatile stocks in US Market 3.2%
Stable Share Price: GNMS.F has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: GNMS.F's weekly volatility (8%) has been stable over the past year.
About the Company Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Show more Genmab A/S Fundamentals Summary How do Genmab's earnings and revenue compare to its market cap? GNMS.F fundamental statistics Market cap US$13.12b Earnings (TTM ) US$653.19m Revenue (TTM ) US$2.76b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) GNMS.F income statement (TTM ) Revenue DKK 19.84b Cost of Revenue DKK 774.00m Gross Profit DKK 19.07b Other Expenses DKK 14.37b Earnings DKK 4.70b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 74.02 Gross Margin 96.10% Net Profit Margin 23.69% Debt/Equity Ratio 0%
How did GNMS.F perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/18 07:22 End of Day Share Price 2024/12/18 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Genmab A/S is covered by 45 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew Carlsen ABG Sundal Collier Armelle Moulin AlphaValue Emily Field Barclays
Show 42 more analysts 
